RGLS 5040

Drug Profile

RGLS 5040

Alternative Names: RGLS-5040

Latest Information Update: 07 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Regulus Therapeutics
  • Class Antisense oligonucleotides; MicroRNAs
  • Mechanism of Action MicroRNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cholestasis

Most Recent Events

  • 12 Jun 2017 Discontinued - Preclinical for Cholestasis in USA (Parenteral)
  • 06 Dec 2016 Preclinical trials in Cholestasis in USA (Parenteral)
  • 06 Dec 2016 Regulus plans to file an IND application with the US FDA for Cholestasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top